Insider · CIK 0001405253
Jeffrey S Farrow
Files at ACHV (ACHIEVE LIFE SCIENCES, INC.), TARS (Tarsus Pharmaceuticals, Inc.). First filing Mar 20, 2025, latest Jun 17, 2026.
In brief
Jeffrey S Farrow files SEC Form 4 as officer and director at TARS (Tarsus Pharmaceuticals, Inc.), and also at ACHV (ACHIEVE LIFE SCIENCES, INC.). Since Mar 20, 2025, Jeffrey S Farrow has reported 0 open-market buys worth $0 and 4 open-market sells worth $2.0M, the latest filed on Jun 17, 2026.
A track record needs three past buys with six months of prices behind them; Jeffrey S Farrow has 0, so none is measured yet.
The newest scored trade: sold $877k of TARS on Jun 16, 2026, filed Jun 17, 2026, scored 43 (moderate). In the last 12 months: 0 buys worth $0 and 2 sells worth $1.3M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TARS: Tarsus Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 43Moderate | Tarsus Pharmaceuticals, Inc. | $877k 14,396 shares | -20% | +57% from low-26% from high | |
| 52Moderate | Tarsus Pharmaceuticals, Inc. | $440k 6,430 shares | -13% | +80% from low-15% from high | |
| 44Moderate | Tarsus Pharmaceuticals, Inc. | $550k 13,608 shares | -27% | +27% from low-31% from high | |
| 40Moderate | Tarsus Pharmaceuticals, Inc. | $178k 3,724 shares | -14% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 16, 2026 | TARS Tarsus Pharmaceuticals, Inc. | 14,396 0.03% of outstanding | $877k | Jun 16, 2026 | $440k |
| Mar 19, 2026 | TARS Tarsus Pharmaceuticals, Inc. | 2,186 0.01% of outstanding | $146k | Mar 19, 2026 | $293k |
| Mar 18, 2026 | TARS Tarsus Pharmaceuticals, Inc. | 2,133 0.01% of outstanding | $147k | Mar 18, 2026 | $147k |
| Mar 17, 2026 | TARS Tarsus Pharmaceuticals, Inc. | 2,111 0.01% of outstanding | $147k | Mar 17, 2026 | none |
| Jun 17, 2025 | TARS Tarsus Pharmaceuticals, Inc. | 13,608 0.03% of outstanding | $550k | Jun 17, 2025 | $178k |
| Mar 20, 2025 | TARS Tarsus Pharmaceuticals, Inc. | 1,186 0.00% of outstanding | $59k | Mar 20, 2025 | $119k |
| Mar 19, 2025 | TARS Tarsus Pharmaceuticals, Inc. | 1,254 0.00% of outstanding | $59k | Mar 19, 2025 | $59k |
| Mar 18, 2025 | TARS Tarsus Pharmaceuticals, Inc. | 1,284 0.00% of outstanding | $59k | Mar 18, 2025 | none |
Transactions
Every row this insider has filed, 26 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | ACHV ACHIEVE LIFE SCIENCES, INC. | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jul 29, 2026 |
| Jul 27, 2026 | ACHV ACHIEVE LIFE SCIENCES, INC. | AGrant or award Restricted Stock Unit (RSU)derivative | +16,700 | $0.00 | $0 | 16,700 | Jul 29, 2026 |
| Jun 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Common Stock | +27,881 | - | - | 71,197 | Jun 17, 2026 |
| Jun 16, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -14,396 | $60.95 | $877k | 56,801 | Jun 17, 2026 |
| Jun 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -27,881 | $0.00 | $0 | 27,882 | Jun 17, 2026 |
| May 29, 2026 | ACHV ACHIEVE LIFE SCIENCES, INC. | AGrant or award Stock Option (right to buy)derivative | +47,250 | $0.00 | $0 | 47,250 | Jun 2, 2026 |
| Mar 17, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,111 | $69.42 | $147k | 47,635 | Mar 19, 2026 |
| Mar 18, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,133 | $68.71 | $147k | 45,502 | Mar 19, 2026 |
| Mar 19, 2026 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,186 | $67.00 | $146k | 43,316 | Mar 19, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Common Stock | +13,042 | - | - | 49,746 | Mar 17, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -8,020 | $0.00 | $0 | 16,040 | Mar 17, 2026 |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -5,022 | $0.00 | $0 | 15,067 | Mar 17, 2026 |
| Mar 5, 2026 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +30,724 | $0.00 | $0 | 30,724 | Mar 9, 2026 |
| Mar 5, 2026 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +19,306 | $0.00 | $0 | 19,306 | Mar 9, 2026 |
| Jun 16, 2025 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Common Stock | +27,881 | - | - | 50,312 | Jun 18, 2025 |
| Jun 17, 2025 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -13,608 | $40.42 | $550k | 36,704 | Jun 18, 2025 |
| Jun 16, 2025 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -27,881 | $0.00 | $0 | 55,763 | Jun 18, 2025 |
| Mar 18, 2025 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,284 | $46.29 | $59k | 24,871 | Mar 20, 2025 |
| Mar 19, 2025 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,254 | $47.40 | $59k | 23,617 | Mar 20, 2025 |
| Mar 20, 2025 | TARS Tarsus Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,186 | $50.11 | $59k | 22,431 | Mar 20, 2025 |
| Mar 15, 2025 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Common Stock | +8,019 | - | - | 26,155 | Mar 18, 2025 |
| Mar 17, 2025 | TARS Tarsus Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -8,019 | $0.00 | $0 | 24,060 | Mar 18, 2025 |
| Mar 5, 2025 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +30,628 | $0.00 | $0 | 30,628 | Mar 7, 2025 |
| Mar 5, 2025 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +20,089 | $0.00 | $0 | 20,089 | Mar 7, 2025 |
| Mar 7, 2024 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +47,500 | $0.00 | $0 | 47,500 | Mar 11, 2024 |
| Mar 7, 2024 | TARS Tarsus Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +32,079 | $0.00 | $0 | 32,079 | Mar 11, 2024 |
Questions about Jeffrey S Farrow
Answered from the filings on this page, as of the latest one.
Is Jeffrey S Farrow buying or selling?
In the last 12 months Jeffrey S Farrow reported 0 open-market buys worth $0 and 2 open-market sells worth $1.3M on SEC Form 4; the latest was sold $877k of TARS on Jun 16, 2026. Grants, option exercises and tax withholding are not counted.
How did Jeffrey S Farrow's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jeffrey S Farrow has 0.
Where does Jeffrey S Farrow file Form 4?
Jeffrey S Farrow has filed Form 4 at TARS (Tarsus Pharmaceuticals, Inc.) as See Remarks; ACHV (ACHIEVE LIFE SCIENCES, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.